| 摘要 |
Disclosed is a hydroxyapatite (HA) incorporating an alpha-emitting radionuclide chosen from the group 211At, 212Bi, 223Ra, 224Ra, 225Ac, 227Th or a beta-emitting radionuclide chosen from the group of 212Pb, 211Pb, 213Bi or 225Ra, wherein the HA comprises a cation that is bivalent, trivalent, such as calcium, strontium, barium, bismuth, yttrium, lanthanum, or lead, or a mixture of such cations and is not combined or co-sedimented with magnetic iron. Also disclosed is a process for preparing the said HA. The use of the said HA for the manufacture of a medicament of a cancerous disease is also disclosed.
|
